World Federation of Hemophilia
-
WFH Announces multi-year humanitarian aid agreement with Green Cross
The World Federation of Hemophilia and the Green Cross Corporation signed a three-year agreement on Monday July 25, 2016, to contribute a total of six...
-
Hemophilia Alliance Supports U.S. Healthcare Professional Continued Training
WFH USA is pleased to announce the first installment of Hemophilia Alliance Travel Grants which will begin this year in time for the WFH 2016...
-
vCJD case reported in patient with a different genotype
The first case of variant Creutzfeldt-Jakob disease (vCJD) in a patient that is genetically different from all previous confirmed cases has been been reported in...
-
WFH 2016 World Congress program focuses on the future of treatment
Over the past decade, the global bleeding disorders community has witnessed great strides in the research of new treatments and methods of care. During the...
-
EMA investigating rare adverse events associated with hepatitis C treatment
The European Medicines Agency (EMA) has started a review of medicines known as direct-acting antivirals used for treating chronic hepatitis C infection. There have been...
-
Access barrier to groundbreaking hepatitis C treatments
New medications unveiled in the last two years have revolutionized the treatment of hepatitis C (HCV) drastically improving patients’ chances of a cure. The challenge...
-
WFH Collaboration with EHC and EAHAD in Estonia
For many national hemophilia organizations, the path to improving hemophilia healthcare in their countries comes from the many contributions from both global and regional partners....
-
Providing guidance on product selection
There are several new treatment products for bleeding disorders available today and over the next couple of years, even more will likely become available to...
-
The Forum for Latin America
Over the last few decades, many of the World Federation of Hemophilia (WFH) national member organizations (NMOs) in Latin America have expanded their networks, become...
-
World Federation of Hemophilia product selection statement
The selection of safe, effective medicinal products is the responsibility of national regulatory and health agencies. In the case of clotting factor concentrates, whether plasma-derived...
